PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA
Clinical Trial Grant
Awarded By
Regeneron Pharmaceuticals, Inc.
Start Date
October 10, 2025
End Date
October 16, 2030
Awarded By
Regeneron Pharmaceuticals, Inc.
Start Date
October 10, 2025
End Date
October 16, 2030